Medicine
Inqovi 100 mg/35 mg tablet
Inqovi 100 mg/35 mg tablet is a prescription medicine containing Cedazuridine and Decitabine for oral use, marketed by Taiho Pharmaceutical, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted from 15°C to 30°C…
Key facts
- Active ingredient (INN)
- Cedazuridine and Decitabine
- Brand
- Inqovi
- Strength
- 100 mg/35 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 1 blister pack
- Marketing authorisation holder
- Taiho Pharmaceutical
- Manufacturer
- Taiho Pharmaceutical
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted from 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01BC58 Cedazuridine and Decitabine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 7 July 2020
- Identifiers
- RxCUI 2384457, 2384458, 2384464 +1DailyMed set ID 91a0f80b-f865-4d06-a40d-4d148d99ee71NDC 64842-0727Application NDA212576
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 blister pack in 1 carton / 5 tablet, film coated in 1 blister pack | 64842-0727-9 | Taiho Pharmaceutical | 25 August 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Cedazuridine and Decitabine is a fixed-dose combination medicine indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Cedazuridine and Decitabine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Cedazuridine and DecitabineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- INQOVI prescribing information (Taiho Pharmaceutical) · U.S. National Library of Medicine, DailyMed
- Inaqovi: European public assessment report (EPAR) · European Medicines Agency
Need Inqovi 100 mg/35 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.